4,449 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the first quarter, HoldingsChannel.com reports. The firm purchased 4,449 shares of the biopharmaceutical company’s stock, valued at approximately $628,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Sowell Financial Services LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 54.9% in the 1st quarter. Sowell Financial Services LLC now owns 333 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 118 shares during the last quarter. Ellevest Inc. raised its stake in shares of Alnylam Pharmaceuticals by 24.1% in the 4th quarter. Ellevest Inc. now owns 695 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 135 shares during the period. CWM LLC raised its stake in shares of Alnylam Pharmaceuticals by 14.3% in the 1st quarter. CWM LLC now owns 800 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 100 shares during the period. Signaturefd LLC raised its stake in shares of Alnylam Pharmaceuticals by 98.5% in the 4th quarter. Signaturefd LLC now owns 953 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 473 shares during the period. Finally, MUFG Americas Holdings Corp raised its stake in shares of Alnylam Pharmaceuticals by 34.5% in the 4th quarter. MUFG Americas Holdings Corp now owns 974 shares of the biopharmaceutical company’s stock valued at $127,000 after acquiring an additional 250 shares during the period. Institutional investors own 91.85% of the company’s stock.

In other news, insider Akshay Vaishnaw sold 3,706 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, April 19th. The shares were sold at an average price of $137.67, for a total value of $510,205.02. Following the completion of the transaction, the insider now directly owns 22,908 shares of the company’s stock, valued at approximately $3,153,744.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO John Maraganore sold 33,979 shares of Alnylam Pharmaceuticals stock in a transaction dated Thursday, May 13th. The shares were sold at an average price of $130.78, for a total transaction of $4,443,773.62. Following the completion of the transaction, the chief executive officer now directly owns 248,744 shares of the company’s stock, valued at $32,530,740.32. The disclosure for this sale can be found here. Insiders sold a total of 40,417 shares of company stock valued at $5,328,126 over the last ninety days. Company insiders own 2.30% of the company’s stock.

ALNY opened at $163.26 on Friday. The business has a 50-day moving average of $139.63. The company has a market cap of $19.19 billion, a P/E ratio of -21.65 and a beta of 1.25. Alnylam Pharmaceuticals, Inc. has a 1-year low of $119.29 and a 1-year high of $178.41. The company has a debt-to-equity ratio of 0.21, a current ratio of 4.99 and a quick ratio of 4.84.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Wednesday, April 28th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.75) by $0.04. The company had revenue of $177.57 million during the quarter, compared to the consensus estimate of $176.93 million. Alnylam Pharmaceuticals had a negative net margin of 153.49% and a negative return on equity of 76.92%. During the same quarter in the previous year, the firm earned ($1.62) EPS. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.19 earnings per share for the current year.

A number of equities analysts have recently commented on ALNY shares. Royal Bank of Canada reissued a “hold” rating on shares of Alnylam Pharmaceuticals in a research note on Sunday, February 14th. Guggenheim reaffirmed a “neutral” rating and set a $162.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, March 1st. Needham & Company LLC reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, April 20th. Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $206.00 to $205.00 and set an “overweight” rating on the stock in a research note on Friday, April 30th. Finally, Citigroup downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $170.00 to $175.00 in a research note on Friday, February 12th. Seven analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $172.07.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Article: Diversification For Individual Investors

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.